Published in J R Soc Med on April 01, 2005
The Use of Phage-Displayed Peptide Libraries to Develop Tumor-Targeting Drugs. Int J Pept Res Ther (2006) 1.11
Furin targeted drug delivery for treatment of rhabdomyosarcoma in a mouse model. PLoS One (2010) 1.00
The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived? Br J Clin Pharmacol (2008) 0.99
The role of molecular imaging in the development of dendritic cell-based cancer vaccines. Eur J Nucl Med Mol Imaging (2005) 0.83
The hallmarks of cancer. Cell (2000) 113.05
Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 83.56
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med (2004) 30.26
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med (2002) 19.60
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol (2004) 9.73
Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol (1995) 9.03
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol (1998) 8.40
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol (2004) 7.87
Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol (2002) 6.09
Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature (1986) 4.19
Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol (2001) 3.38
Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood (2003) 3.37
Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol (2001) 2.95
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol (2001) 2.71
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol (2001) 2.71
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol (2002) 2.41
Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol (2000) 2.38
Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res (1988) 2.36
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res (2001) 2.35
Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol (2003) 2.14
Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol (1999) 1.87
Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol (2001) 1.87
A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res (1984) 1.85
Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol (2003) 1.57
The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat (1995) 1.46
Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol (2001) 1.42
A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol (1991) 1.42
Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm (1997) 1.40
Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol (2000) 1.31
Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol (2003) 1.31
Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin Pharmacokinet (1995) 1.29
ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene (1991) 1.27
Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control (2002) 1.25
Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin Oncol (1999) 1.22
A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res (2003) 1.09
Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer. Clin Cancer Res (2003) 1.02
Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol (2002) 0.98
Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart. Semin Oncol (2001) 0.93
Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas. Int J Cancer (2000) 0.92
Humanized antibodies. Immunol Today (1993) 0.91
A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. Clin Cancer Res (2000) 0.91
Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1D10--a humanized human leucocyte antigen DR antibody. Br J Haematol (2002) 0.85
Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol (2002) 0.85
Targeted molecules in small cell lung cancer. Semin Oncol (2004) 0.85
Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts. Clin Cancer Res (2004) 0.84
Future of monoclonal antibodies in the treatment of hematologic malignancies. Cancer Control (2002) 0.83
A phase I study of 99mTc-hR3 (DiaCIM), a humanized immunoconjugate directed towards the epidermal growth factor receptor. Nucl Med Commun (2002) 0.81
Epratuzumab in non-Hodgkin's lymphomas. Curr Treat Options Oncol (2004) 0.81
Renal cell carcinoma: novel treatments for advanced disease. Curr Opin Urol (2003) 0.80
Relationship of DNA ploidy and S-phase fraction to survival after first recurrence of breast cancer. Acta Oncol (1994) 0.79
Phase II trial of KW2189 in patients with advanced malignant melanoma. Am J Clin Oncol (2002) 0.77
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature (2012) 5.84
Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. Cell Rep (2013) 2.37
Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med (2008) 2.27
Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis. Clin Cancer Res (2005) 1.99
Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab (2004) 1.97
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res (2013) 1.92
AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis (2006) 1.66
FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. Int J Oncol (2009) 1.46
Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. Genome Res (2011) 1.32
A 2009 update on the treatment of patients with hormone receptor-positive breast cancer. Clin Breast Cancer (2009) 1.27
Altered tissue 3'-deoxy-3'-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography. Clin Cancer Res (2009) 0.98
Angiosarcoma of the breast following surgery and radiotherapy for breast cancer. Nat Clin Pract Oncol (2008) 0.97
The role of SRC-3 in human breast cancer. Nat Rev Clin Oncol (2009) 0.95
Value of whole body 18FDG-PET to identify the active site of gestational trophoblastic neoplasia. J Reprod Med (2006) 0.92
Severe thrombocytopenia induced by a single infusion of trastuzumab. Clin Breast Cancer (2008) 0.89
[11C]choline positron emission tomography in estrogen receptor-positive breast cancer. Clin Cancer Res (2009) 0.89
Activity of eribulin mesylate in heavily pretreated breast cancer granted access via the Cancer Drugs Fund. Future Oncol (2013) 0.87
TGFβ1-Endo180-dependent collagen deposition is dysregulated at the tumour-stromal interface in bone metastasis. J Pathol (2011) 0.87
Biological basis of [¹¹C]choline-positron emission tomography in patients with breast cancer: comparison with [¹⁸F]fluorothymidine positron emission tomography. Nucl Med Commun (2011) 0.85
Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breast. J Cutan Pathol (2007) 0.85
Human epidermal growth factor receptor 2-positive breast cancer relapsing post-adjuvant trastuzumab: pattern of recurrence, treatment and outcome. Clin Breast Cancer (2011) 0.84
Maintenance of fertility following treatment with temozolomide for a high grade astrocytoma. J Neurooncol (2005) 0.83
Surgical oncology: why biopsying metastatic breast cancer should be routine. Nat Rev Clin Oncol (2010) 0.82
Adjuvant radiotherapy for breast cancer. BMJ (2008) 0.82
Efficacy and toxicity of nonpegylated liposomal doxorubicin in breast cancer. Expert Rev Anticancer Ther (2008) 0.79
Burkitt's lymphoma and previous AIDS-defining illnesses are not prognostic factors in AIDS-related non-Hodgkin's lymphoma. J Clin Oncol (2005) 0.79
Role of fulvestrant in the management of postmenopausal breast cancer. Expert Rev Anticancer Ther (2011) 0.78
Reproducibility of [11C]choline-positron emission tomography and effect of trastuzumab. Clin Cancer Res (2010) 0.78
Patient attitudes towards undergoing additional breast biopsy for research. Breast (2013) 0.78
Imaging of cellular proliferation in liver metastasis by [18F]fluorothymidine positron emission tomography: effect of therapy. Phys Med Biol (2012) 0.78
Prior exposure to chemotherapy: a marker of sensitivity and selection for antiangiogenic therapy in breast cancer? Expert Rev Anticancer Ther (2013) 0.76
Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer. Breast Cancer Res Treat (2014) 0.76
Gene-expression profiling and identification of patients at high risk of breast cancer. Lancet (2002) 0.75
Value of SERMs in postmenopausal women. Lancet (2004) 0.75
Breast cancer metastasizing to the tongue. Can J Surg (2008) 0.75
The ethnic profile of triple-negative breast cancer. Onkologie (2008) 0.75
Hypocalcaemia after intravenous bisphosphonate: adjuvant bisphosphonate is not currently accepted practice. BMJ (2004) 0.75
Stem-cell therapy for myocardial diseases. Lancet (2004) 0.75
The Vincotube System: a design solution to prevent the accidental administration of intrathecal vinca alkaloids. J Clin Oncol (2004) 0.75
Does ER-betacx really have no clinical importance in tamoxifen-treated breast cancer patients? J Clin Oncol (2008) 0.75
Palifermin and chemotherapy-induced oral mucositis. N Engl J Med (2005) 0.75
Fulvestrant in advanced breast cancer following tamoxifen and aromatase inhibition: a single center experience. Breast J (2009) 0.75
ChIPing away at breast cancer. Lancet Oncol (2012) 0.75
An unusual triple-negative breast carcinoma. Histopathology (2009) 0.75
Is the presence of small volume disease in the sentinel node an indication for axillary clearance? Breast (2012) 0.75
Poor reception? Lancet (2009) 0.75